Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. (0JDK.L) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Iovance Biotherapeutics, Inc. (0JDK.L), covering cash flow, earnings, and balance sheets.
Iovance Biotherapeutics, Inc. (0JDK.L) Income Statement & Financial Overview
View the income breakdown for Iovance Biotherapeutics, Inc. 0JDK.L across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $49.32M | $73.69M | $58.55M | $31.11M |
| Cost of Revenue | $49.74M | $45.54M | $39.82M | $31.37M |
| Gross Profit | -$417000.00 | $28.15M | $18.73M | -$262000.00 |
| Gross Profit Ratio | -$0.008 | $0.38 | $0.32 | -$0.008 |
| R&D Expenses | $76.88M | $72.22M | $68.25M | $62.08M |
| SG&A Expenses | $43.92M | $42.50M | $39.55M | $34.19M |
| Operating Expenses | $120.80M | $114.73M | $107.80M | $96.27M |
| Total Costs & Expenses | $170.54M | $160.27M | $147.62M | $133.02M |
| Interest Income | $3.22M | $9.57M | $4.005M | $3.35M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $11.06M | $11.69M | $11.15M | $10.86M |
| EBITDA | -$110.16M | -$74.89M | -$77.92M | -$91.05M |
| EBITDA Ratio | -$2.23 | -$1.02 | -$1.33 | -$2.93 |
| Operating Income | -$121.22M | -$86.58M | -$89.07M | -$101.91M |
| Operating Income Ratio | -$2.46 | -$1.17 | -$1.52 | -$3.28 |
| Other Income/Expenses (Net) | $3.22M | $9.57M | $4.005M | $3.35M |
| Income Before Tax | -$118.001M | -$77.001M | -$85.06M | -$98.56M |
| Income Before Tax Ratio | -$2.39 | -$1.04 | -$1.45 | -$3.17 |
| Income Tax Expense | -$1.84M | $1.56M | -$1.52M | -$1.46M |
| Net Income | -$116.16M | -$78.56M | -$83.54M | -$97.10M |
| Net Income Ratio | -$2.36 | -$1.07 | -$1.43 | -$3.12 |
| EPS | -$0.36 | -$0.26 | -$0.28 | -$0.34 |
| Diluted EPS | -$0.36 | -$0.26 | -$0.28 | -$0.34 |
| Weighted Avg Shares Outstanding | $322.87M | $304.89M | $303.27M | $284.82M |
| Weighted Avg Shares Outstanding (Diluted) | $322.87M | $304.89M | $303.27M | $284.82M |
Over the past four quarters, Iovance Biotherapeutics, Inc. demonstrated steady revenue growth, increasing from $31.11M in Q2 2024 to $49.32M in Q1 2025. Operating income reached -$121.22M in Q1 2025, maintaining a consistent -246% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$110.16M, reflecting operational efficiency. Net income dropped to -$116.16M, with EPS at -$0.36. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan